Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAvMed Aldurazyme (laronidase) Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Aldurazyme (laronidase) prior authorization for MPS I

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requirements and clinical criteria for prior authorization and continuation of intravenous Aldurazyme (laronidase) for members with mucopolysaccharidosis type I (MPS I); applies to providers requesting medical benefit coverage from AvMed.

    Policy Summary
    PayerAvMed
    PolicyAldurazyme (laronidase) prior authorization for MPS I
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization with required documentation including definitive diagnosis (molecular testing or enzyme activity) and baseline uGAG and clinical measures.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial authorization duration
    12 monthsRenewal authorization duration
    ≥6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age
    92/28dDose limit (vials)
    667/7dHCPCS unit limit

    Coverage Criteria for Aldurazyme (laronidase)

    Initial Therapy

    Covered when ALL of the following are met for initial authorization:

    Initial Authorization Criteria: Member is ≥ 6 months of age

    Definitive Diagnosis

    • ONE of: Detection of biallelic pathogenic mutations in the IDUA gene by molecular genetic testing
    • ONE of: Fibroblast or leukocyte alpha-L-iduronidase (IDUA) enzyme activity level < 10% of the lower limit of the normal range of the measuring laboratory

    Phenotype and Cognitive Status

    • ONE of: Diagnosis of Hurler (severe) or Hurler-Scheie (attenuated)
    • ONE of: Diagnosis of Scheie (attenuated) with moderate to severe symptoms
    Baseline Biomarker: Documented baseline urinary glycosaminoglycan (uGAG) value

    Baseline Clinical Measures

    • For members ≥ 6 years: Percent predicted FVC ≤ 77% and/or 6-minute walk test (must stand independently for 6 minutes and walk ≥ 5 m); joint range of motion; left ventricular hypertrophy; growth; quality of life (CHAQ/HAQ/MPS HAQ)
    • For members 6 months to < 6 years: Cardiac status; upper airway obstruction during sleep; growth velocity; mental development; FVC; and/or 6-minute walk test (must stand independently for 6 minutes and walk ≥ 5 m)
    Operational Note: All criteria must be met and supporting documentation provided

    Continuation Therapy

    Covered when ALL of the following are met for continuation of therapy:

    Continuation Baseline: Member continues to meet all initial authorization criteria (see Initial Therapy)
    Tolerability: Absence of unacceptable toxicity from the drug (examples include anaphylaxis, severe hypersensitivity reactions, acute respiratory complications, acute cardiorespiratory failure, severe infusion reactions)
    Cognitive Status: Member does not have progressive or irreversible severe cognitive impairment
    Biomarker Response: Documented reduction in urinary glycosaminoglycan (uGAG) levels compared to pretreatment baseline

    Clinical Benefit

    Continuation of Aldurazyme (laronidase) is not permitted when the member experiences unacceptable toxicity attributable to the drug. Examples of unacceptable toxicities include anaphylaxis, severe hypersensitivity reactions, acute respiratory complications, acute cardiorespiratory failure, and severe infusion reactions. Such toxicities preclude continuation of therapy and should be documented in the medical record.

    Covered Indications and Diagnostic Confirmation

    Confirmation of MPS I to establish eligibility for laronidase therapy

    Definitive diagnosis of MPS I can be established when ONE of the following is met:

    ONE of: Detection of biallelic pathogenic mutations in the IDUA gene by molecular genetic testing
    ONE of: Fibroblast or leukocyte alpha-L-iduronidase (IDUA) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory

    Member Eligibility Requirements

    To be eligible for initiation of Aldurazyme (laronidase) the member must meet all initial authorization criteria: be aged ≥ 6 months; have a definitive diagnosis of MPS I established by either detection of biallelic pathogenic IDUA mutations on molecular testing or fibroblast or leukocyte alpha-L-iduronidase enzyme activity <10% of the lower limit of normal; have a qualifying clinical diagnosis (Hurler or Hurler‑Scheie, or Scheie with moderate to severe symptoms); have absence of severe cognitive impairment; and have documented baseline laboratory and age‑appropriate clinical measures including urinary glycosaminoglycan (uGAG) and the specified functional assessments (for ≥6 years: percent predicted FVC ≤77% and/or 6‑minute walk test with the ability to stand independently and walk ≥5 m, joint ROM, LVH, growth, quality‑of‑life measures; for 6 months to <6 years: cardiac status, sleep‑related upper airway obstruction, growth velocity, mental development, FVC, and/or 6‑minute walk test).

    Billing Codes and Quantity Limits

    Requested Drug HCPCSHCPCSCovered
    J1931Aldurazyme (laronidase) IV solution
    Quantity limits
    Vial size2.9 mg per vial
    Vial count limit92 vials per 28 days
    HCPCS billable unit limit667 billable units every 7 days

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Aldurazyme (laronidase) J1931 (medical benefit). Initial authorizations are for 6 months; continuation authorizations are for 12 months and require documentation of ongoing benefit and absence of unacceptable toxicity. Incomplete, incorrect, or illegible information on the request form may delay or deny authorization.

    • J1931 (Aldurazyme) — Medical benefit
    • Initial Authorization: 6 months
    • Continuation Authorization: 12 months — requires documentation of benefit and absence of unacceptable toxicity
    Note

    Samples and Prior Therapy Verification

    Use of samples to initiate therapy does not meet preauthorization criteria. Previous therapies will be verified via pharmacy paid claims or submitted chart notes. For urgent reviews, contact AvMed Pre-Authorization Department per plan guidance.

    • Samples do not meet step-edit/preauthorization criteria

    Key Definitions

    Definitive diagnosis (MPS I)
    DefinitionDefinitive diagnosis of MPS I established by detection of biallelic pathogenic IDUA gene mutations or by enzyme testing
    Molecular criterionDetection of biallelic pathogenic mutations in the IDUA gene by molecular genetic testing
    Enzyme activity criterionFibroblast or leukocyte alpha-L-iduronidase (IDUA) enzyme activity <10% of the lower limit of normal for the measuring laboratory

    Background on Mucopolysaccharidosis Type I (MPS I)

    Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder caused by pathogenic variants in the IDUA gene resulting in deficient alpha‑L‑iduronidase activity and accumulation of glycosaminoglycans. Clinical manifestations vary from severe (Hurler) to attenuated (Hurler‑Scheie, Scheie) phenotypes; non‑central nervous system manifestations (cardiac, respiratory, skeletal, growth, and functional limitations) are the primary targets for enzyme replacement therapy with laronidase (Aldurazyme).

    Policy Summary
    PayerAvMed
    PolicyAldurazyme (laronidase) prior authorization for MPS I
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization with required documentation including definitive diagnosis (molecular testing or enzyme activity) and baseline uGAG and clinical measures.
    SourceLink
    On This Page
    Coverage Criteria for Aldurazyme (laronidase)Covered Indications and Diagnostic ConfirmationMember Eligibility RequirementsBilling Codes and Quantity LimitsProvider Actions, Documentation, and Prior AuthorizationKey DefinitionsBackground on Mucopolysaccharidosis Type I (MPS I)
    For members ≥ 6 years: Stability or improvement in percent predicted FVC and/or 6-minute walk test; increased joint range of motion; decreased left ventricular hypertrophy; improved growth; improved quality of life (clinically meaningful change in CHAQ/HAQ/MPS HAQ)
  1. For members 6 months to < 6 years: Stability or improvement in cardiac status; upper airway obstruction during sleep; growth velocity; mental development; FVC; and/or 6-minute walk test
  2. Operational Note: All continuation criteria must be met and documented
  3. Previous therapies will be verified through pharmacy paid claims or submitted chart notes
  4. For urgent reviews, call AvMed Pre-Authorization Department
  5. Documentation Required

    Required Clinical Documentation

    Provide diagnostic and baseline data to support the clinical criteria. Requests lacking the required documentation may be delayed or denied.

    • Definitive diagnosis of MPS I confirmed by one of: detection of biallelic pathogenic IDUA mutations OR fibroblast/leukocyte IDUA enzyme activity < 10% of the lab's lower limit of normal
    • Documented diagnosis details (Hurler, Hurler-Scheie, or Scheie with moderate to severe symptoms) and absence of severe cognitive impairment
    • Baseline urinary glycosaminoglycan (uGAG) value
    • Baseline functional measures: For ≥6 years — percent predicted FVC, 6-minute walk test (must stand independently for 6 minutes and walk ≥5 meters), joint range of motion, left ventricular hypertrophy, growth, quality of life (CHAQ/HAQ/MPS HAQ); For 6 months to <6 years — cardiac status, upper airway obstruction during sleep, growth velocity, mental development, FVC, and/or 6-minute walk test
    Documentation Required

    Form and Provider Identification

    The prescribing physician must sign and clearly print their name on the request form (preprinted stamps are not valid). Include complete member and prescriber demographic and contact information to avoid delays.

    • Prescriber signature and date (hand-signed; preprinted stamps not valid)
    • Member name, AvMed ID, date of birth
    • Prescriber name, NPI, office contact name, phone number, fax number
    • Drug name/form/strength, dosing schedule, length of therapy, diagnosis and ICD code, weight and date obtained, quantity/units requested, and location/site of administration or specialty pharmacy
    Denial Risk

    Missing Supporting Documentation

    All clinical criteria boxes checked on the form must be supported by corresponding documentation (lab results, diagnostics, chart notes). Requests may be denied if supporting documentation is missing.

    • To support each checked clinical criterion, provide corresponding documentation (e.g., genetic testing reports, enzyme assay results, uGAG, pulmonary function tests, 6-minute walk test, cardiac evaluations, growth records, QoL assessments)
    • Incomplete or missing supporting documentation may result in denial of the request